Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

Study acronym: SWITCH-ON
StatusTerminated
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: Following a reassessment, it was concluded that continuation of the study would no longer achieve its scientific objectives originally set out for the study. Show 6 more changesShow less
    • Final enrollment: 1 participants — under 1% of the 215 planned
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion date changed from estimate of Oct 2028 to Aug 31, 2026
    • Study sites: 5 to 4
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 8 of 12 entries
  2. Start date changed from estimate of Jan 2026 to May 8, 2026
    • Trial sites expanded: 2 → 5 locations
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
Trial Details
NCT Number NCT07313176
Lead Sponsor Britannia Pharmaceuticals Ltd.
Conditions
(from sponsor)		 Advanced Parkinson Disease
Related terms Movement Disorders, Neurodegenerative Diseases, Parkinson Disease
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov